The Improving Effect of Autologous Stromal Vascular Fraction (SVF) in Adipose Tissue on Skin Grafting

NCT ID: NCT02546882

Last Updated: 2015-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to observe whether the transplantation of autologous stromal vascular fraction (SVF) in adipose tissue is safe and its effect on improving the texture and contracture of skin grafting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Reconstruction of large scale skin defect is still a challenge for clinical surgeons. The application of skin grafting works as an important choice, however, the strong contracture and poor appearance limit its wide application in scar repair. The stromal vascular fraction (SVF) of adipose tissue is a group of heterogeneous cells including multipotential mesenchymal cells, preadipocytes, endothelial cells, fibroblasts, macrophages and smooth muscle cells. Previous researches have reported that SVF could secrete various angiogenic growth factors in vitro and enhance neovascularisation of ischaemic tissue in vivo. The Adipose-derived Stem cells in the SVF are multipotential stem cells which have the ability to regenerate, while differentiating to become adipose tissue and help to improve the texture of the grafted skin. Besides, SVF is easy to be harvested in large numbers with less donor injury and can be used directly after isolation without in vitro culture, which makes it a good alternative for regenerative medicine.This study is to observe the effect of autologous SVF on improving the texture and contracture of skin grafting.

Patients requiring skin graft of 2 symmetry parts of the body between the age of 3 and 70 years will be enrolled and randomized into two groups, named as the experimental group with SVF transplantation and the control group with no cell transplantation. Patients from the experimental group will have a fat aspiration on the surgery day. The adipose tissue in abdomen or thigh will be digested at 37 °C for 60 min with 0.2% collagenase IV. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is SVF. The SVF will be resuspended in saline and transplanted between the grafted skin and the wound with 1 million cells for 1 cm2 area. Skin thickness, texture, contracture and colour will be observed to measure the effect of SVF on skin grafting post treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin; Deformity, Due to Scar

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

stromal vascular fraction

The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).

Group Type EXPERIMENTAL

stromal vascular fraction

Intervention Type BIOLOGICAL

1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.

saline

1 ml saline without cells will be used as placebo.

Group Type PLACEBO_COMPARATOR

saline

Intervention Type DRUG

1 ml saline was injected for 1 cm2 area.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stromal vascular fraction

1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.

Intervention Type BIOLOGICAL

saline

1 ml saline was injected for 1 cm2 area.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

heterogeneous cell populations isolated from adipose tissue normal saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* With symmetrical scar or soft tissue deficiencies requiring skin graft therapy.
* Age of 3 to 70.
* Have no underlying disease except skin scar deformity.
* Have enough healthy donor site skin for both sides of receiving area.

Exclusion Criteria

* Not fit for skin graft treatment;
* Evidence of infection, ischemia, ulcer or other pathological changes within the targeting area which defined as not suitable for skin grafting; or history of delayed healing, radiational therapy;
* Significant renal, cardiovascular, hepatic and psychiatric diseases;
* Significant medical diseases or infection (including but not limited to the carrier of hepatitis B virus or HIV);
* BMI \>30;
* Alcohol abuse
* History of any hematological disease, including leukopenia , thrombocytopenia, or thrombocytosis;
* Evidence of malignant diseases or unwillingness to participate.
Minimum Eligible Age

3 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

West China Hospital

OTHER

Sponsor Role collaborator

Guangzhou General Hospital of Guangzhou Military Command

OTHER

Sponsor Role collaborator

Second Affiliated Hospital of Suzhou University

OTHER

Sponsor Role collaborator

The First People's Hospital of Zhaoqing City

UNKNOWN

Sponsor Role collaborator

Wuhan Third Hospital

OTHER

Sponsor Role collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Qing-Feng Li

MD, PhD, Professor, Head of the Department of Plastic and Reconstructive Surgery, Shanghai 9th People'sHospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Qingfeng Li, MD, PhD

Role: STUDY_DIRECTOR

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shanghai Ninth People's Hospital, Affliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Qingfeng Li, MD, PhD

Role: CONTACT

0086 21 63089567

Hua Li, MD, PhD

Role: CONTACT

0086 18621871963

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Qingfeng Li, MD, PhD

Role: primary

0086 21 63089567

Hua Li, MD, PhD

Role: backup

0086 18621871963

References

Explore related publications, articles, or registry entries linked to this study.

Qin J, Cheng C, Huang RL, He J, Zhou S, Tan PC, Zhang T, Fang B, Li Q, Xie Y. Isolation of the Stromal Vascular Fraction Using a New Protocol with All Clinical-Grade Drugs: From Basic Study to Clinical Application. Aesthetic Plast Surg. 2024 Nov;48(22):4702-4711. doi: 10.1007/s00266-024-04221-9. Epub 2024 Jul 10.

Reference Type DERIVED
PMID: 38987318 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012BAI11B03

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2012BAI11B03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microsurfaced Grafts in Deep Burn Wounds
NCT04589442 RECRUITING PHASE4